

Date of preparation: 2020-09-14

Issuers short name: MABION S.A.

Subject matter:

Conclusion of Memorandum of Understanding on potential cooperation regarding a product that may be a vaccine for Covid-19 disease

Legal basis: Article 17 _1_ MAR - confidential information.

Content of the report:

Management Board of Mabion S.A. ("Company") informs about conclusion of a Memorandum of Understanding ("MoU") with Vaxine Pty Ltd. based in Australia ("Vaxine") on 14 September 2020 regarding arrangements in terms of potential process development, manufacturing and commercialization of the product Covax-19™, which may constitute a vaccine for the Covid-19 disease caused by the Sars-Cov-2 virus ("Product"), with particular emphasis on the markets of Poland and the European Union.

Vaxine is an Australian biotechnology company focused on the development of innovative vaccines against seasonal and pandemic influenza, Covid-19, hepatitis B and Japanese encephalitis. Covax-19™ is a product developed by Vaxine, based on a scalable vaccine platform utilizing an insect cell-based recombinant spike protein in combination with its proprietary Advax™ adjuvant to enhance both antibody and T-cell immune responses against the co-administered antigen. Covax-19™ is currently in Phase I clinical trials and also has appropriate approvals to start Phase II clinical trials in Australia, following Phase I results.

The MoU states that the purpose of the parties is to negotiate and conclude, if the parties deem it appropriate, agreements in relation to the manufacture of the Product by Mabion, process work to be undertaken, and commercialization of the Product by Mabion on the agreed markets, and before concluding agreements - to conduct mutual due diligence and cooperate in arranging future financing or reimbursement from government or EU funds.

The Company reserves that the MoU is intentional and non-binding, and its conclusion does not prejudice the conclusion of the agreement or cooperation of the parties in the future. Each party may terminate the MoU if the parties do not conclude appropriate agreements by October 30, 2020, or in the event of a negative result of due diligence in the opinion of the party concerned.

At the same time, the Company ensures that the potential establishment of the aforementioned cooperation will not affect in negative manner the implementation of the Company's existing projects, and in particular ensures that the development and commercialization of the MabionCD20 drug will remain the priority of the Company's activities.